Australian-US biotech Opthea Ltd has reported disappointing phase 3 results with its lead drug for vision-robbing disease wet age-related macular degeneration (AMD), throwing its future into doubt.

After years of high borrowing costs, many older homeowners are considering the idea of tapping into their home equity to borrow money right now. And, while there are a number of affordable ways to do ...

Resistance of malignant cells to cytotoxic drugs is one of the main reasons for the failure of chemotherapy. Experimental systems including in vitro cultured cell lines have identified several ...

Ionis has committed to a phase 3 programme for its antisense therapy for rare genetic disorder Angelman syndrome, just weeks after Biogen decided against exercising an option to license the drug. The ...

An estimated 98 million Americans have pre-diabetes, according to the Centers for Disease Control and Prevention. This condition affects 541 million people globally. Don’t let the ‘pre’ fool you, ...

Not every AI video generator will be right for your project or budget. Here's how to choose one that's right for you. Katelyn is a writer with CNET covering artificial intelligence, including chatbots ...

Move over, chatbots and image generators: This is the era of AI video generators. Don't miss any of our unbiased tech content and lab-based reviews. Add CNET as a preferred Google source. Many of ...

In what could be a major sentiment booster for Indian markets, foreign portfolio investors have turned buyers with a Rs 6,480 crore investment in the month of October, thus reversing a three-month ...

Minerva secures $80 million up front and up to an additional $80 million subject to the full exercise of Tranche A warrants. Minerva and the FDA have defined a path forward for roluperidone’s clinical ...